13.02USD-0.53%Mkt Cap: 223.40M USDP/E: —Last update: 2026-05-26
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stag…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap223.40M USD
Enterprise Value-42.11M USD
Revenue (TTM)36.68M USD
Gross Profit-12.07M USD
Net Income (TTM)-76.68M USD
Revenue/Share2.144 USD
Last Price13.02 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.23
PEG—
EV/EBITDA0.71
EV/Revenue-1.15
P/S6.08
P/B-3.23
EPS (TTM)-5.02
EPS (Forward)-4.03
52W Range
11.9522% of range16.77
52W High16.77 USD
52W Low11.95 USD
Profitability
Gross Margin-32.91%
Oper. Margin-88.01%
EBITDA Margin-160.95%
Profit Margin-411.88%
ROE-36.99%
ROA-27.55%
Growth
Revenue Growth1148.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.13M USD
CapEx (TTM)1.45M USD
FCF Margin—
FCF Yield—
Net Debt-265.17M USD
Net Debt/EBITDA4.49
Balance Sheet
Debt/Equity0.02
Current Ratio13.04
Quick Ratio12.91
Book Value/Sh-4.0420 USD
Cash/Share15.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)25.00 USD
Target Range25.00 USD – 25.00 USD
# Analysts2
Ownership
Shares Out.17.11M
Float15.76M
Insiders4.27%
Institutions92.48%
Short Interest
Short Ratio7.1d
Short % Out.22.08%
Shares Short3.02M
Short (prev mo.)1.91M
Technical
SMA 5013.36 (-2.5%)
SMA 20013.63 (-4.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)296.00K
Avg Vol (10d)173.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—